ViiV Healthcare announces £3 million global fund to research the impact of COVID-19 on the HIV community and fill gaps in prevention, treatment and care during the pandemic

Deborah Waterhouse, CEO at ViiV Healthcare said: “Our mission is to leave no person living with HIV behind and in these unprecedented times, it’s more important than ever that we use our resources and expertise to do just that. To contribute to finding solutions, ViiV Healthcare is proud to announce the Global HIV and COVID-19 Emergency Fund. Through this fund, we can support research about the impact of COVID-19 on people living with HIV that is urgently needed. We will also be able to provide support to local community organisations who are grounded in the response to the pandemic and those who have been impacted by COVID-19 to allow them to continue the important work they are doing to support the HIV community. We know their support of the broader health system will help save lives.”

The ViiV Healthcare Global HIV and COVID-19 Emergency Response Fund will be divided equally between two programmes and grants will be available through a request for proposal (RFP) process. The Research Emergency Response Fund will make available up to £1.5 million to support scientific research about the impact of COVID-19 on people living with HIV. The Community Emergency Response Fund will make available up to £1.5 million to support community-based activities that address the specific challenges faced by people living with HIV during this pandemic. 

Community Emergency Response Fund
ViiV Healthcare will seek applications from community organisations to support their work in addressing the specific challenges that have arisen for people living with HIV or affected by HIV as a result of the COVID-19 pandemic. Through the £1.5 million Community Emergency Response Fund, grants will be made available to support ongoing access to critical HIV prevention, care and outreach services, differentiated models of service delivery, short term payments for critical community staff, and community monitoring and feedback on the impact of COVID-19 to HIV services and support.  The Community Emergency Fund is not intended for the purchase of pharmaceutical products.

The Community Emergency Response Fund will support existing grantees of ViiV Healthcare’s Positive Action or Government Affairs (GA) or Global Public Health (GPH). Click on the links below to find out more about proposed materials as well as additional information on eligibility criteria and how to apply.

• Positive Action US Grantees and select COVIDRESPONSE
• Positive Action Global, GA and GPH Grantees

Requests for proposals will be open from 27 April through 15 May. The proposals will be reviewed by an internal ViiV Healthcare panel and successful applicants notified by 25 May.

Our actions to support the broader global response
We are also proud of everything our majority shareholder, GSK, is doing to contribute to solutions to the COVID-19 pandemic. This includes the research and production of candidate COVID-19 vaccines and the groundbreaking collaboration recently announced between GSK and Sanofi, bringing together two of the world’s largest vaccine companies to fight COVID-19. Along with GSK, we are also involved in a number of partnerships and initiatives to respond to COVID-19 and are working together to conduct screening and research into new medicines as well as helping frontline health workers and offering expertise where we can.

For more information about ViiV Healthcare’s HIV and COVID-19 Emergency Response Fund, please visit our website.